NEUROMETRIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.46 USD | +1.13% |
|
+3.72% | +23.89% |
| Apr. 19 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
| Apr. 19 | Sector Update: Health Care Stocks Rise Friday Afternoon | MT |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to NeuroMetrix Fourt...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
Calendar
2024-07-17
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +23.89% | 8.86M | |
| -4.84% | 182B | |
| +0.56% | 110B | |
| -3.35% | 68.11B | |
| +2.39% | 50.53B | |
| +9.36% | 44.8B | |
| +2.70% | 40.7B | |
| +3.43% | 26.53B | |
| +13.67% | 25.02B | |
| -0.32% | 24.96B |
- Stock Market
- Equities
- NURO Stock
- News NeuroMetrix, Inc.
- Transcript : NeuroMetrix, Inc., Q4 2021 Earnings Call, Jan 27, 2022
